Copyright
©The Author(s) 2017.
World J Clin Oncol. Apr 10, 2017; 8(2): 100-105
Published online Apr 10, 2017. doi: 10.5306/wjco.v8.i2.100
Published online Apr 10, 2017. doi: 10.5306/wjco.v8.i2.100
Figure 3 Adapting the study data to our clinic.
A proposed algorithm to treat second line metastatic renal cell carcinoma patients according to tumor growth rate and patients’ characteristics. TGR: Tumor-growth rate; TKI: Tyrosine kinase inhibitor; LEN: Lenvatinib; EVE: Everolimus.
- Citation: Grande E, Martínez-Sáez O, Gajate-Borau P, Alonso-Gordoa T. Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. World J Clin Oncol 2017; 8(2): 100-105
- URL: https://www.wjgnet.com/2218-4333/full/v8/i2/100.htm
- DOI: https://dx.doi.org/10.5306/wjco.v8.i2.100